Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ORIC 
Oric Pharmaceuticals Inc (ORIC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ORIC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $18
1 Year Target Price $18
| 10 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.15% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.05B USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 12 | Beta 1.63 | 52 Weeks Range 3.90 - 14.67 | Updated Date 09/16/2025 |
52 Weeks Range 3.90 - 14.67 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.69% | Return on Equity (TTM) -43.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 767745799 | Price to Sales(TTM) - |
Enterprise Value 767745799 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 97123000 | Shares Floating 63296993 |
Shares Outstanding 97123000 | Shares Floating 63296993 | ||
Percent Insiders 6.94 | Percent Institutions 99.21 |
Upturn AI SWOT
Oric Pharmaceuticals Inc
Company Overview
History and Background
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer. Founded in 2014, Oric went public in 2020.
Core Business Areas
- RORu03b3 Antagonist Program: Developing ORIC-101, an antagonist of the glucocorticoid receptor, in various cancers.
- PRC2 Inhibitor Program: Developing ORIC-533, an inhibitor of PRC2, for the treatment of acute myeloid leukemia (AML) and other cancers.
- CD73 Inhibitor Program: Developing ORIC-944, an A2A adenosine receptor antagonist, for various cancers.
Leadership and Structure
Jacob Chacko, MD, is the CEO. The company has a board of directors and a management team with expertise in drug development and oncology.
Top Products and Market Share
Key Offerings
- ORIC-101: A glucocorticoid receptor antagonist currently in clinical trials. Market share data is not yet applicable as it is pre-commercial. Competitors include companies developing other hormonal therapies for cancer, such as AstraZeneca, Novartis, and Pfizer.
- ORIC-533: A PRC2 inhibitor also in clinical trials, targeting acute myeloid leukemia (AML). Market share data is not applicable as it is pre-commercial. Competitors include companies developing AML treatments, such as AbbVie, Astellas Pharma, and Bristol Myers Squibb.
- ORIC-944: A CD73 inhibitor also in clinical trials. Market share data is not applicable as it is pre-commercial. Competitors include companies developing anti-CD73 therapies for cancer, such as Arcus Biosciences and Gilead Sciences.
Market Dynamics
Industry Overview
The oncology market is large and growing, with significant unmet needs, especially in overcoming resistance to existing therapies. There is increasing investment and innovation in targeted therapies and immunotherapies.
Positioning
Oric Pharmaceuticals is positioned as a company focused on overcoming resistance mechanisms in cancer through targeted therapies.
Total Addressable Market (TAM)
The total oncology market is estimated to be worth hundreds of billions of dollars. Oric is targeting niche areas within this market by addressing resistance to existing treatments, positioning them to capture a portion of this expanding market. Their specific TAM depends on clinical trial success.
Upturn SWOT Analysis
Strengths
- Targeted approach to overcome resistance mechanisms
- Strong scientific leadership
- Promising early clinical data for multiple programs
Weaknesses
- Clinical-stage company with no commercial products
- High reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Potential for breakthrough therapies in areas of unmet need
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through in-licensing or acquisition
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing similar therapies
- Patent expirations
Competitors and Market Share
Key Competitors
- Arcus Biosciences (RCUS)
- Gilead Sciences (GILD)
- AbbVie (ABBV)
- Astellas Pharma (ALPMY)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Oric Pharmaceuticals faces competition from both large pharmaceutical companies and smaller biotech firms developing similar therapies. Oric's advantage lies in its targeted approach to overcoming resistance mechanisms and its focus on specific patient populations.
Growth Trajectory and Initiatives
Historical Growth: Oric Pharmaceuticals has not had any historical growth in revenue because they are a clinical stage company and are pre-revenue.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates vary depending on the perceived likelihood of success for the company's pipeline.
Recent Initiatives: Oric Pharmaceuticals's recent initiatives include advancing its clinical programs, exploring partnerships, and optimizing its cost structure.
Summary
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company that is working to create novel therapies for cancer. Currently, the company has no revenue as it has not had any FDA approved products. However, recent initiations that have been taken to optimize cost structure will help the company in the future as it will not burn through its cash reserves so fast. The company's success depends heavily on clinical trial results for their key products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Oric Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oric Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-04-24 | President, CEO & Director Dr. Jacob M. Chacko M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.oricpharma.com |
Full time employees 128 | Website https://www.oricpharma.com | ||
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.